GW Pharma (GWPH) Posts Smaller Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress
August 7, 2018 4:01 PM EDT- Epidiolex® (cannabidiol) oral solution approved by FDA and on track to be launched in Fall -- Conference call today at 4:30 p.m. ET -
LONDON and CARLSBAD, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, announces financial results for the third quarter ended 30 June 2018.
The recent FDA approval of Epidiolex represents a major medical advance for patients with... More
